Intelligence Profile
Clinical Applications
Estradiol 0.01% vaginal cream is used primarily to treat symptoms of menopause, such as vaginal atrophy and related conditions. This treatment helps increase estrogen levels in vaginal tissues, alleviating symptoms like dryness, itching, and irritation.
Clinical Applications:
Atrophic Vaginitis:
- A Phase 3 clinical trial (NCT02195986) compared estradiol vaginal cream to Estrace® cream in postmenopausal women with atrophic vaginitis. This trial suggests its effectiveness in treating symptoms associated with vaginal atrophy in postmenopausal females.
Genitourinary Syndrome of Menopause (GSM):
- An ongoing study (NCT05672901) is examining the cream's efficacy in managing GSM, indicating its relevance for this syndrome.
Overactive Bladder Syndrome:
- A Phase 4 study (NCT05221021) is recruiting participants to compare vaginal estradiol with oral beta-3 agonist, exploring its potential benefit for women with overactive bladder syndrome.
Recurrent Urinary Tract Infections (UTIs):
- Another Phase 4 trial (NCT06353269) is investigating adherence to vaginal estrogen therapy in women with recurrent UTIs linked to hypoestrogenism, suggesting its potential usefulness in this context.
Current evidence supports the use of estradiol 0.01% vaginal cream primarily for symptoms related to menopause, such as vaginal atrophy, but ongoing research may further define its use for conditions like overactive bladder syndrome and recurrent UTIs.
Disclaimer: This is a general overview based on available studies and not personalized medical advice. For individual concerns, consult a healthcare professional.